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Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely
used; however, they are also nephrotoxic with both acute
and chronic effects on kidney function. Here we determined
NSAID prescribing before and after estimated GFR (eGFR)
reporting and evaluate renal function in patients who used
NSAIDs but stopped these after their first eGFR report.
A population-based longitudinal analysis using a record-
linkage database was conducted with the GFR estimated
using the four-variable equation from the MDRD study and
analyzed by trend test, paired t-test, and logistic regression
modeling. Prescriptions for NSAIDs significantly decreased
from 39,459 to 35,415 after implementation of eGFR
reporting from the second quarter of 2005 compared with
the first quarter of 2007. Reporting eGFR was associated with
reduced NSAID prescriptions (adjusted odds ratio, 0.78).
NSAID prescription rates in the 6 months before April 2006
were 18.8, 15.4, and 7.0% in patients with CKD stages 3,
4, and 5 and 15.5, 10.7, and 6.3%, respectively, after eGFR
reporting commenced. In patients who stopped NSAID
treatment, eGFR significantly increased from 45.9 to 46.9,
23.9 to 27.1, and 12.4 to 26.4ml/min per 1.73m2 in 1340
stage 3 patients, 162 stage 4 patients, and 9 stage 5 patients,
respectively. Thus, NSAID prescribing decreased after the
implementation of eGFR reporting, and there were significant
improvements in estimated renal function in patients who
stopped taking NSAIDs. Hence, eGFR reporting may result in
safer prescribing.
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Chronic kidney disease (CKD) is a worldwide public health
problem with an increasing incidence and prevalence,
particularly in elderly populations.1–4 Nonsteroidal anti-
inflammatory drugs (NSAIDs) are widely used in elderly
populations. They are also nephrotoxic agents with both
acute and chronic effects on kidney function.5 Previous
studies have shown that NSAIDs are associated with a
decrease in kidney function.6–8 Data from Scotland have
shown a decrease in the use of NSAIDs over the period
2004–2008.9 In April 2006, the Scottish Renal Registry
and the National Service Framework (NSF) recommended
that reporting of creatinine measurements should be
accompanied by an estimated glomerular filtration rate
(eGFR). The aims of this study were to determine NSAID
prescribing before and after the implementation of eGFR
reporting and to evaluate renal function in patients who used
NSAIDs but stopped these after eGFR reporting was
implemented.
RESULTS
NSAID prescribing rates during the two time intervals
Prescriptions of NSAIDs decreased after the implementation
of eGFR reporting (39,459 in the second quarter of 2005 vs.
35,415 in the first quarter of 2007, Po0.01; Figure 1). NSAID
prescribing rates in patients with CKD stages 3, 4, and 5 were
24.5% (7746/31,600), 18.3% (257/1406), and 7.7% (20/259)
in the year before April 2006 and 18.3% (5052/27,474),
12.1% (196/1625), and 7.4% (26/352) in the year after eGFR
reporting commenced (Figure 2). The corresponding
figures for NSAID prescribing 6 months on either side
of 1 April 2006 were 18.8, 15.4, and 7.0% (before eGFR
reporting) and 15.5, 10.7, and 6.3% (after eGFR reporting),
respectively.
Examining the changes in renal function in patients
who used NSAIDs
A total of 1522 patients had two reported eGFRs with a time
interval of4180 days and had NSAID prescriptions recorded
before eGFR reporting but stopped after the first reported
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eGFR measurement. They were all in stages 3, 4, and 5 (1340,
162, and 20 patients in stages 3, 4, and 5, respectively).
Table 1 shows the characteristics of patients by CKD stage.
Patients in stage 5 were significantly younger than patients in
stages 3 and 4. There were no differences in gender,
socioeconomic status, type of NSAIDs used, and diabetes
history between the patients in the different CKD stages.
Medical notes were reviewed for patients in the stage 5 group.
Of the 20 patients studied, 11 were on dialysis and
their results were excluded from the analysis in Figure 3a.
The average eGFR in each stage (Figure 3a) was improved
significantly in all three groups, with the largest improvement
in stage 5 patients. eGFR increased from 45.9 to 46.9ml/min
per 1.73m2 (n¼ 1340, Po0.01), 23.9 to 27.1ml/min per 1.73m2
(n¼ 162, Po0.01), and 12.4 to 26.4ml/min per 1.73m2 (n¼ 9,
Po0.01), respectively. The absolute differences were 1.0, 3.2,
and 13.9ml/min per 1.73m2 for stages 3, 4, and 5,
respectively. Figure 3b shows the results in patients with a
3-month follow-up time (1700, 181, and 24 patients for
stages 3, 4, and 5, respectively). The absolute difference of
eGFR was similar in stage 3 patients, and bigger in patients
with stages 4 and 5 (3.7 vs. 3.2ml/min per 1.73m2, and 16.8
vs. 14.3ml/min per 1.73m2, respectively).
A sensitivity analysis was performed by using the closest
eGFR after the last NSAID was prescribed. In this case, more
patients were included in the study (n¼ 15,212). There were
10,669 patients in stage 3, 3163 patients in stage 4, and 1380
patients in stage 5. The absolute changes in eGFR were  0.3,
4.2, and 7.4ml/min per 1.73m2 for stages 3, 4, and 5,
respectively.
Implementation of eGFR reporting was associated with
reduced NSAID prescribing in patients who had creatinine
and eGFR measurements (n¼ 62,716) during the study
period (adjusted odds ratio, 0.78 95% confidence interval
0.75–0.82).
DISCUSSION
We observed a decrease in NSAID prescribing in Tayside
after eGFR reporting was introduced on 1 April 2006.
eGFR reporting was not associated with decline in the use of
other cardiovascular drugs, such as angiotensin-converting
enzyme inhibitors or angiotensin receptor-blocking drugs.
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Figure 1 | Frequency of nonsteroidal anti-inflammatory drugs
(NSAIDs), angiotensin-converting enzyme/angiotensin receptor
blocker (ACE/ARB) inhibitors, and diuretics prescriptions in
Tayside between 2005 and 2007. quart, quarter.
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Figure 2 | Nonsteroidal anti-inflammatory drug (NSAID)
prescribing rate in the 1 year on either side of the
implementation date of 1 April 2006. CKD, chronic kidney disease.
Table 1 | Characteristics of patients by CKD stages
CKD stage
P-value
3 4 5
n¼ 1340 n¼ 162 n¼ 20
Age, mean (s.d.) 74.3 (10.1) 78.0 (9.0) 65.4 (17.8) o0.01
Gender, n (%)
Male 461 (34.4) 45 (27.8) 8 (40.0) 0.20
Female 879 (65.6) 117 (72.2) 12 (60.0)
Socioeconomic status, n (%)
1 (most deprived) 215 (16.2) 30 (18.5) 6 (30.0) 0.40
2 222 (16.7) 27 (16.7) 5 (25.0)
3 249 (18.8) 28 (17.3) 1 (5.0)
4 413 (31.1) 47 (29.0) 3 (15.0)
5 (most affluent) 228 (17.2) 30 (24.7) 5 (25.0)
NSAID type, n (%)
Diclofenac 472 (35.2) 52 (32.1) 7 (35.0) 0.18
Ibuprofen 387 (28.9) 39 (24.1) 3 (15.0)
Others 481 (35.9) 71 (43.8) 10(50.0)
Diabetes history, n (%) 333 (24.9) 40 (24.7) 6 (30.0) 0.87
Use of diuretics, n (%)
Before interval 842 (85.4) 132 (13.4) 12 (1.2) o0.01
After interval 871 (85.8) 133 (13.1) 11 (1.1) o0.01
Use of ACE/ARB inhibitors, n (%)
Before interval 734 (86.4) 104 (12.2) 12 (1.4) 0.07
After interval 850 (88.1) 108 (11.2) 7 (0.7) 0.02
Calculated eGFR before intervala
Stage 2 107 (8.2) 0 (0.0) 1 (5.0) o0.01
Stage 3 1183 (90.0) 53 (32.9) 1 (5.0)
Stage 4 24 (1.8) 107 (66.5) 7 (35.0)
Stage 5 0 (0.0) 1 (0.6) 11 (55.0)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor
blocker; CKD, chronic kidney disease; eGFR; estimated glomerular filtration rate;
NSAID, nonsteroidal anti-inflammatory drug.
aA total of 1495 patients had creatinine results.
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Our study provides evidence that eGFR reporting was
associated with improved estimates of renal function in
patients who stopped NSAID treatment. By providing
additional information, in addition to serum creatinine,
eGFR reporting may provide additional renal benefit and
reduced prescribing of NSAIDs in primary care.
CKD and NSAID use in elderly people are major
challenges to health-care systems with aging populations.
CKD is a risk factor for multiple adverse outcomes such as
kidney failure, cardiovascular disease, cognitive impairment,
and death.10 However, despite the importance of recognizing
CKD, it may be missed when serum creatinine alone is used
as a marker of renal function, because of confounders,
including muscle mass, age, sex, and ethnicity; eGFR
reporting was introduced mainly in recognition of this.
NSAIDS are known to affect renal function most likely by
inhibiting renal prostaglandin production, an effect that is
modified by factors such as sodium status.11,12 NSAIDs,
except aspirin, should generally be avoided in CKD patients if
possible. However, in practice, patients with CKD are likely
to be older and to have multiple comorbid conditions or
symptoms that lead to increased use of NSAIDs. NSAIDs
have been associated with acute kidney injury and disease
progression in those with CKD, leading to sodium retention,
edema, hypertension, and hyperkalemia.5,13,14 Therefore, it is
important to monitor renal function in patients taking
NSAIDs. Previous studies have shown that early recognition,
intervention, and management of patients with CKD by
physicians lead to slow progression of the disease and disease
complications.15–18 However, a recent American survey
showed that among patients with CKD stage X3, NSAIDs
were prescribed in 5% of patients, and that awareness of the
association between NSAIDs and kidney disease was not
associated with reduced NSAID use (3.8% aware vs. 3.9%
unaware; P¼ 0.979).15 Our data suggest that awareness of
CKD in patients prescribed NSAIDs increased after the
introduction of eGFR reporting, and that the reduction in
NSAID prescribing was associated with improvement in renal
function in patients with CKD after they stopped taking
NSAIDs. We observed a substantial improvement in eGFR in
stage 5 patients. To clarify the clinical status of patients at the
time of the estimates of GFR and to make sure the results
were not affected by dialysis patients, we further reviewed the
medical notes of stage 5 patients after the main analysis.
The results of eGFR change in stage 5 patients after excluding
the dialysis patients (n¼ 11) remained the same. This
suggested that our findings were valid. Furthermore, within
stage 5 patients, we observed decreased eGFRs between the
eGFR before the date of the last NSAID prescription (within
2 months) and the eGFR after the date of last NSAID
prescription (within 2 months), with a mean change of
 4ml/min per 1.73m2. This supports the evidence that
NSAIDs are associated with a decreased renal function.
Although only 9 patients were included in this group, similar
results were also observed in a further sensitivity analysis that
included 1380 patients in this group when using the closest
eGFR after the last NSAID. eGFR reporting did not affect the
community prescribing of diuretics, angiotensin-converting
enzyme inhibitors, or angiotensin receptor blockers. This
might be explained by the perceived antihypertensive and
nephroprotective benefits of these drugs, resulting in
clinicians being reluctant to discontinue them.
The main strength of this study is its population-based
cohort design, with complete regional biochemistry data,
which is unique. However, the study has some limitations.
First, the study was confined to a single National Health
Service (NHS) region, and it is possible that the association
between NSAID prescribing and CKD reporting may be
different in other regions. A further study such as a
questionnaire survey of physician behavior would strengthen
the study finding. Second, the study period was historical.
We do not know whether the prescribing behaviors in recent
years were sustained or accelerated or lapsed. A follow-up
study would be able to answer this question. Third,
the estimated eGFR did not correct for ethnicity because
we did not have this information. However, 97% of Tayside
population are Caucasians, and therefore this is unlikely to
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Figure 3 | The average of estimated glomerular filtration rate
(eGFR) in nonsteroidal anti-inflammatory drug (NSAID) users
who stopped NSAIDs after the first reported eGFR measurement.
(a) Follow-up time¼ 180 days. (b) Follow-up time¼ 90 days.
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have been a major confounder. This is unlikely to be a major
source of misclassification. Fourth, unmeasured risk factors
and confounders may have biased the use of NSAIDs.
However, we have previously shown little impact of
unmeasured risk factors and confounders in the same
population.19 Finally, we did not use a reference method
for assessing glomerular function.
In conclusion, introduction of eGFR reporting may result
in safer prescribing of NSAIDs in primary care.
MATERIALS AND METHODS
The study was conducted in Tayside, Scotland, using the MEMO
(Medicines Monitoring Unit) record-linkage database held by the
Health Informatics Centre in the University of Dundee.20 The MEMO
database covers a geographically compact population and serves
B400,000 patients in the NHS in Scotland, 97% of whom are white.
In brief, this database contains several data sets including all dispensed
community prescriptions, hospital discharge data, biochemistry data,
and other data that are linked by a unique patient identifier, the
community health index number. The data have been validated and
made anonymous for the purposes of research as approved by the
government-appointed guardians of patient confidentiality. The project
was also approved by the Tayside committee on research medical ethics
and the Tayside Caldicott Guardians.
Study population
Subjects resident in Tayside and registered with a general
practitioner between January 2005 and December 2007 formed the
study population.
Study subjects
Subjects were those who had at least one NSAID prescription or
serum creatinine measurement between April 2005 and March 2007.
There are two time intervals for this study period, 1 year on either
side of the eGFR implementation date of 1 April 2006. For each
patient, eGFR and creatinine were followed up for 6 months.
Estimation of eGFR
Glomerular filtration rate was estimated using the four-variable
equation from the Modification of Diet in Renal Disease (MDRD)
study21 (the four variables used in this equation are serum
creatinine, age, sex, and ethnicity). An information sheet about
eGFR reporting was circulated to all users of laboratory services in
March 2006. For creatinine results reported before April 2006, GFR
was estimated retrospectively. The creatinine assay was a rate-
blanked compensated Jaffe method, measured on a Roche modular
P analyzer (Roche Diagnostics, Lewes, UK). There was no change in
method throughout the study period. External quality assurance of
the creatinine assay was through the United Kingdom National
External Quality Assessment Scheme (UK NEQAS). Bias was
acceptable and consistent throughout.
Kidney disease was stratified using the system advocated by the
American National Kidney Foundation Kidney Disease Outcomes
Initiative (NKF KDOQI).22 Briefly, CKD is stratified into five stages,
defined as follows: stage 1, eGFRX90.0ml/min per 1.73m2; stage 2,
eGFR 60.0–89.9ml/min per 1.73m2; stage 3, eGFR 30.0–59.9ml/min
per 1.73m2; stage 4, eGFR 15.0–29.9ml/min per 1.73m2; and stage
5, eGFRo15.0ml/min per 1.73m2.
Outcome variables
The primary outcome variable was the change in NSAID prescribing
rates during the two time intervals (1 year on either side of the eGFR
implementation date). The secondary outcome was the change in
renal function as estimated by the four-variable MDRD
equation (eGFR) in patients who were on NSAID treatment but
who stopped after the first eGFR report. Patients in the analysis of
renal function change were those who wereX18 years old, as eGFR
measured by MDRD is only valid in adults. Medical notes were
retrospectively reviewed for stage 5 patients by a renal physician
to establish whether the patients were dialysis patients after an
additional ethical approval was obtained.
Statistical analysis
Data were summarized as mean (s.d.)/median (interquartile range)
for continuous variables and number of subjects (percent) for
categorical variables. The w2, paired t-test, and analysis of variance
tests were performed to determine significant differences. Rates of
NSAID prescribing in CKD patients were compared between the
users who did not get an eGFR report and who had an eGFR report
(that is, before the implementation of eGFR reporting vs. after the
implementation of eGFR reporting). Potential confounding by
indication for eGFR reporting such as age, gender, socioeconomic
status, comorbidity of diabetes, and use of diuretics, angiotensin-
converting enzyme inhibitors, and angiotensin receptor blockers was
adjusted for in a logistic regression model. All statistical analyses
were performed using SAS version 9.1 (SAS Institute, Cary, NC).
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